Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer

Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer

The clinical application of immune checkpoint inhibitors (ICIs) has led to dramatic changes in the treatment strategy for patients with advanced non-small cell lung cancer (NSCLC). Despite the observation of improved overall survival in NSCLC patients treated with ICIs, their efficacy varies greatly...

Full description

Bibliographic Details
Main Authors: Yosuke Miura, Noriaki Sunaga
Format: Article
Language:English
Published: MDPI AG 2018-07-01
Series:Cancers
Subjects:
non-small cell lung cancer
immunotherapy
immune checkpoint inhibitor
oncogenic driver
epidermal growth factor receptor (EGFR)
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)
programmed death ligand-1 (PD-L1)
tumor microenvironment.
Online Access:http://www.mdpi.com/2072-6694/10/8/245

Internet

http://www.mdpi.com/2072-6694/10/8/245

Similar Items